Diesel Emissions

Debate between Lord O'Shaughnessy and Lord Bishop of Carlisle

Wednesday 5th December 2018 Lords Chamber

[Lord O’Shaughnessy]

The important issue is that, whoever holds the post, the Mayor of London has the power to take action. It is notable that that has not been reinstated by a Labour Mayor of London, so maybe there was something in that decision in the first place.

[The Lord Bishop of Carlisle]

My Lords, does the Minister agree that, while electric cars are being developed, trees, plants, shrubs and especially hedges can make a very useful contribution to the absorption of harmful emissions, as well as having a therapeutic value for those who grow them and those who enjoy them? Can he tell us of any plans the Government may have to encourage the greening of our towns and cities?

[Lord O’Shaughnessy]

The right reverend Prelate makes an excellent point, with which I completely concur. We are making good progress in increasing the number of ultra-low emission cars. There is a huge amount that we can do to green our cities. I know that this is a priority of both the Ministry of Housing, Communities and Local Government and Defra. They will have specific details, and I will write to him with an answer.

Chronic Lymphocytic Leukaemia: Ibrutinib

Debate between Lord O'Shaughnessy and Lord Bishop of Carlisle

Thursday 7th June 2018 Lords Chamber

[Lord O'Shaughnessy]

I thank the noble Lord for his question. There are two important issues here. First, on this treatment as a first-line treatment, the evidence that was put into NICE by the company itself did not propose its use as a first-line treatment, which is why it has been proposed as a second-line treatment. It is important to distinguish there. However, clearly there is this apparent discrepancy between the NICE guidelines and NHS England. I have, obviously, investigated this, subsequent to the meeting with my noble friend and sufferers. NHS England’s view is that its commissioning guidelines are consistent with the commissioning when the drug was in the cancer drugs fund, and the full NICE guidance, but I also know that that is not satisfactory to some of the patients suffering from this illness who have been in remission for three years. That is precisely what I want to get to the bottom of next week.

[The Lord Bishop of Carlisle]

My Lords, I am most grateful to the Minister for meeting some of the patients suffering from this terrible disease. Can he tell us whether anyone directly affected by blood cancer was consulted before the initial decision was made by NHS England to restrict access to Ibrutinib? Can he assure the House that NICE guidelines will not often be varied—and then only after consultation with patients?

[Lord O'Shaughnessy]

I thank the right reverend Prelate for that question. As he will know, NICE consults widely with patient groups and others in making its decisions. I am not clear at this stage whether NHS England met patient groups and others in designing its clinical commissioning guidelines, which is of course what I shall investigate next week.